| P2093 | author name string | Julian Falutz | |
| P2860 | cites work | Genetic polymorphisms differently influencing the emergence of atrophy and fat accumulation in HIV-related lipodystrophy | Q58377861 |
| | Studies of body composition and fat distribution in HIV-infected and control subjects | Q74605053 |
| | GH/GHRH axis in HIV lipodystrophy | Q80689329 |
| | Mitochondrial dysfunction in AIDS and its treatment | Q81110778 |
| | Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies | Q24597052 |
| | The role of protease inhibitors in the pathogenesis of HIV-associated lipodystrophy: cellular mechanisms and clinical implications | Q24598812 |
| | Vitamin D deficiency | Q27860616 |
| | Increasing rates of obesity among HIV-infected persons during the HIV epidemic | Q28473706 |
| | Effects of testosterone supplementation on whole body and regional fat mass and distribution in human immunodeficiency virus-infected men with abdominal obesity | Q33266319 |
| | Serum insulin-like growth factor I (IGF-I), IGF-binding proteins 2 and 3, and the risk for development of malignancies in adults with growth hormone (GH) deficiency treated with GH: data from KIMS (Pfizer International Metabolic Database). | Q33627300 |
| | Vitamin D and risk of cognitive decline in elderly persons | Q33742161 |
| | Insulin resistance, hepatic lipid and adipose tissue distribution in HIV-infected men. | Q33854415 |
| | Effects of switching from lopinavir/ritonavir to atazanavir/ritonavir on muscle glucose uptake and visceral fat in HIV-infected patients | Q33918414 |
| | Immunodeficiency and the risk of serious clinical endpoints in a well studied cohort of treated HIV-infected patients | Q33987654 |
| | HIV Infection, Inflammation, Immunosenescence, and Aging | Q34150710 |
| | Abdominal adiposity in rheumatoid arthritis: association with cardiometabolic risk factors and disease characteristics | Q34233328 |
| | HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER Study | Q34370880 |
| | Role of adipose tissue as an inflammatory organ in human diseases | Q34523574 |
| | Recombinant human growth hormone to treat HIV-associated adipose redistribution syndrome: 12 week induction and 24-week maintenance therapy | Q34641774 |
| | Incomplete peripheral CD4+ cell count restoration in HIV-infected patients receiving long-term antiretroviral treatment | Q34937231 |
| | Bone disease in HIV infection: a practical review and recommendations for HIV care providers | Q35019051 |
| | Association of upper trunk and visceral adipose tissue volume with insulin resistance in control and HIV-infected subjects in the FRAM study | Q35189974 |
| | Fat distribution in men with HIV infection | Q35194387 |
| | Increased intramyocellular lipid accumulation in HIV-infected women with fat redistribution | Q35492338 |
| | Dual-energy X-ray absorptiometry and body composition | Q36089030 |
| | HIV and inflammation | Q36196604 |
| | CD4+ count and risk of non-AIDS diseases following initial treatment for HIV infection | Q36745251 |
| | Waist circumference and cardiometabolic risk: a consensus statement from shaping America's health: Association for Weight Management and Obesity Prevention; NAASO, the Obesity Society; the American Society for Nutrition; and the American Diabetes As | Q36759913 |
| | Low-dose physiological growth hormone in patients with HIV and abdominal fat accumulation: a randomized controlled trial | Q36868568 |
| | Independent associations of insulin resistance with high whole-body intermuscular and low leg subcutaneous adipose tissue distribution in obese HIV-infected women | Q37161855 |
| | The effects of recombinant human leptin on visceral fat, dyslipidemia, and insulin resistance in patients with human immunodeficiency virus-associated lipoatrophy and hypoleptinemia | Q37193194 |
| | Role of viral replication, antiretroviral therapy, and immunodeficiency in HIV-associated atherosclerosis | Q37215251 |
| | Metabolic outcomes in a randomized trial of nucleoside, nonnucleoside and protease inhibitor-sparing regimens for initial HIV treatment. | Q37338133 |
| | Association of plasma vitamin D levels with adiposity in Hispanic and African Americans | Q37341830 |
| | HIV-associated lipodystrophy: from fat injury to premature aging | Q37733151 |
| | Growth hormone, the insulin-like growth factor axis, insulin and cancer risk. | Q37801276 |
| | HIV infection, body composition changes and related metabolic complications: contributing factors and evolving management strategies | Q37860874 |
| | In vitro suppression of the lipogenic pathway by the nonnucleoside reverse transcriptase inhibitor efavirenz in 3T3 and human preadipocytes or adipocytes. | Q38346020 |
| | Gender differences in antiretroviral drug-related adipose tissue alterations. Women are at higher risk than men and develop particular lipodystrophy patterns | Q39015989 |
| | Increased epicardial adipose tissue volume in HIV-infected men and relationships to body composition and metabolic parameters | Q39697756 |
| | Low CD4+ T cell count is a risk factor for cardiovascular disease events in the HIV outpatient study | Q42992133 |
| | Inhibition of mitochondrial function by efavirenz increases lipid content in hepatic cells | Q43011656 |
| | Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension. | Q43184310 |
| | Adipocyte differentiation, mitochondrial gene expression and fat distribution: differences between zidovudine and tenofovir after 6 months | Q43208922 |
| | A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors | Q43613003 |
| | Body composition profiles derived from dual-energy X-ray absorptiometry, total body scan, and mortality | Q43698842 |
| | Impact of switching from lopinavir/ritonavir to atazanavir/ritonavir on body fat redistribution in virologically suppressed HIV-infected adults | Q44494124 |
| | Effects of growth hormone on abnormal visceral adipose tissue accumulation and dyslipidemia in HIV-infected patients | Q44838874 |
| | Growth hormone-releasing hormone in HIV-infected men with lipodystrophy: a randomized controlled trial | Q44975160 |
| | Intra-abdominal fat is a major determinant of the National Cholesterol Education Program Adult Treatment Panel III criteria for the metabolic syndrome | Q44995548 |
| | Buffalo hump seen in HIV-associated lipodystrophy is associated with hyperinsulinemia but not dyslipidemia | Q45239033 |
| | Changes in body composition with ritonavir-boosted and unboosted atazanavir treatment in combination with Lamivudine and Stavudine: a 96-week randomized, controlled study | Q46080787 |
| | Effects of boosted tipranavir and lopinavir on body composition, insulin sensitivity and adipocytokines in antiretroviral-naive adults | Q46266360 |
| | Prevalence of, evolution of, and risk factors for fat atrophy and fat deposition in a cohort of HIV-infected men and women | Q46503398 |
| | A placebo-controlled, dose-ranging study of a growth hormone releasing factor in HIV-infected patients with abdominal fat accumulation | Q46624784 |
| | A 6-month interruption of antiretroviral therapy improves adipose tissue function in HIV-infected patients: the ANRS EP29 Lipostop Study | Q46778393 |
| | Body fat and other metabolic effects of atazanavir and efavirenz, each administered in combination with zidovudine plus lamivudine, in antiretroviral-naive HIV-infected patients | Q46851728 |
| | Metabolic effects of a growth hormone-releasing factor in patients with HIV. | Q46867993 |
| | A single threshold value of waist girth identifies normal-weight and overweight subjects with excess visceral adipose tissue | Q47322846 |
| | Mitochondrial damage in adipose tissue of untreated HIV-infected patients. | Q50551965 |
| | Association of 25(OH)D and PTH with metabolic syndrome and its traditional and nontraditional components. | Q51388179 |
| | A randomized placebo-controlled trial of metformin for the treatment of HIV lipodystrophy. | Q51464591 |
| | Relation between visceral fat and coronary artery disease evaluated by multidetector computed tomography. | Q53323820 |
| | Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety e | Q56896227 |
| | Are dual-energy X-ray absorptiometry regional estimates associated with visceral adipose tissue mass? | Q57760952 |
| | Hypogonadism in HIV-1-infected men is common and does not resolve during antiretroviral therapy | Q58075199 |
| P433 | issue | 3 | |
| P304 | page(s) | 200-208 | |
| P577 | publication date | 2011-09-01 | |
| P1433 | published in | Current HIV/AIDS reports | Q26842190 |
| P1476 | title | Management of fat accumulation in patients with HIV infection | |
| P478 | volume | 8 | |